Observational studyBMJ open2025
Association between high-sensitivity C-reactive protein and bleeding in dual antiplatelet therapy age: a retrospective observational study.
Observational study in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of the present study was to investigate the association of high-sensitivity C-reactive protein (hs-CRP) with bleeding events among patients with acute coronary syndrome (ACS) received dual antiplatelet therapy (DAPT) after percutaneous coronary intervention.
designAn observational and multicentre study was conducted among non-ST-segment elevation ACS (NSTE-ACS).
settingThe study was conducted at five medical centres in China.
participantsThis study retrospectively included 2583 adults with NSTE-ACS between 1 January 2010 and 31 December 2014. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was major bleeding, defined by the Bleeding Academic Research Consortium definition (grades 3-5). The second outcome was death and any bleeding.
results53 (2.1%) patients experienced major bleeding in the hospital. Patients with hs-CRP levels greater than 8.20 mg/L had the highest incidence of in-hospital major bleeding (25 (3.9%), p<0.001) compared with the other groups. Multivariable analysis indicated that hs-CRP was an independent factor associated with in-hospital major bleeding (continuous: adjusted OR=1.01, 95% CI: 1.01 to 1.02, p<0.001; quartiles: adjusted OR for quartile 4 (referring to quartile 1) =3.71, 95% CI: 1.35~10.23, p=0.011), which was further confirmed by subgroup analysis and receiver operating characteristic curves. The restricted cubic spline analysis demonstrated an S-shaped association between hs-CRP and major bleeding. During the 5-year follow-up, there was a significantly high risk of bleeding in patients with higher hs-CRP levels.
conclusionsSystemic inflammation marker hs-CRP in patients with NSTE-ACS who received DAPT is associated with a high risk of in-hospital major bleeding. An S-shaped association was found between hs-CRP and bleeding events. Further studies are warranted to optimise antithrombotic drug therapy in high bleeding risk patients during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.